Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 4.00 |
Expiry date | 2024-06-21 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN").